176 related articles for article (PubMed ID: 36152082)
21. Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation.
Mamon HJ; Dahlberg W; Azzam EI; Nagasawa H; Muto MG; Little JB
Int J Radiat Biol; 2003 Oct; 79(10):817-29. PubMed ID: 14630541
[TBL] [Abstract][Full Text] [Related]
22. HMGB1 induces radioresistance through PI3K/AKT/ATM pathway in esophageal squamous cell carcinoma.
Zhang X; Zou N; Deng W; Song C; Yan K; Shen W; Zhu S
Mol Biol Rep; 2022 Dec; 49(12):11933-11945. PubMed ID: 36260180
[TBL] [Abstract][Full Text] [Related]
23. PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.
Dey N; De P; Leyland-Jones B
Pharmacol Ther; 2017 Jul; 175():91-106. PubMed ID: 28216025
[TBL] [Abstract][Full Text] [Related]
24. Recent nanotechnological interventions targeting PI3K/Akt/mTOR pathway: A focus on breast cancer.
Sharma V; Sharma AK; Punj V; Priya P
Semin Cancer Biol; 2019 Dec; 59():133-146. PubMed ID: 31408722
[TBL] [Abstract][Full Text] [Related]
25. PI3K/AKT Signaling in Breast Cancer Molecular Subtyping and Lymph Node Involvement.
Bonin S; Pracella D; Barbazza R; Dotti I; Boffo S; Stanta G
Dis Markers; 2019; 2019():7832376. PubMed ID: 31781306
[TBL] [Abstract][Full Text] [Related]
26. The cancer-testis antigen a-kinase anchor protein 3 facilitates breast cancer progression via activation of the PTEN/PI3K/AKT/mTOR signaling.
Zhan CH; Ding DS; Zhang W; Wang HL; Mao ZY; Liu GJ
Bioengineered; 2022 Apr; 13(4):8478-8489. PubMed ID: 35322748
[TBL] [Abstract][Full Text] [Related]
27. The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress.
Bahrami A; Khazaei M; Shahidsales S; Hassanian SM; Hasanzadeh M; Maftouh M; Ferns GA; Avan A
J Cell Biochem; 2018 Jan; 119(1):213-222. PubMed ID: 28513879
[TBL] [Abstract][Full Text] [Related]
28. Localisation of specific heparan sulfate proteoglycans during the proliferative phase of brain development.
Ford-Perriss M; Turner K; Guimond S; Apedaile A; Haubeck HD; Turnbull J; Murphy M
Dev Dyn; 2003 Jun; 227(2):170-84. PubMed ID: 12761845
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.
Savva C; De Souza K; Ali R; Rakha EA; Green AR; Madhusudan S
Breast Cancer Res Treat; 2019 May; 175(1):105-115. PubMed ID: 30746633
[TBL] [Abstract][Full Text] [Related]
30. The cytotoxicity of karanjin toward breast cancer cells is involved in the PI3K/Akt signaling pathway.
Yu J; Yang H; Lv C; Dai X
Drug Dev Res; 2022 Nov; 83(7):1673-1682. PubMed ID: 36065628
[TBL] [Abstract][Full Text] [Related]
31. Genetic Association Analysis Implicates Six MicroRNA-Related SNPs With Increased Risk of Breast Cancer in Australian Caucasian Women.
Arif KMT; Bradshaw G; Nguyen TTN; Smith RA; Okolicsanyi RK; Youl PH; Haupt LM; Griffiths LR
Clin Breast Cancer; 2021 Dec; 21(6):e694-e703. PubMed ID: 33952417
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.
Lu PW; Li L; Wang F; Gu YT
J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of RSK4 reverses doxorubicin resistance in human breast cancer cells via PI3K/AKT signalling pathway.
Mei Y; Liao X; Zhu L; Yang H
J Biochem; 2020 Jun; 167(6):603-611. PubMed ID: 31960922
[TBL] [Abstract][Full Text] [Related]
34. ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to DNA-damaging agents in cancer cells.
Chen JH; Zhang P; Chen WD; Li DD; Wu XQ; Deng R; Jiao L; Li X; Ji J; Feng GK; Zeng YX; Jiang JW; Zhu XF
Autophagy; 2015; 11(2):239-52. PubMed ID: 25701194
[TBL] [Abstract][Full Text] [Related]
35. Heparanase-induced GEF-H1 signaling regulates the cytoskeletal dynamics of brain metastatic breast cancer cells.
Ridgway LD; Wetzel MD; Ngo JA; Erdreich-Epstein A; Marchetti D
Mol Cancer Res; 2012 Jun; 10(6):689-702. PubMed ID: 22513363
[TBL] [Abstract][Full Text] [Related]
36. Cell surface heparan sulfate proteoglycans control the response of renal interstitial fibroblasts to fibroblast growth factor-2.
Clayton A; Thomas J; Thomas GJ; Davies M; Steadman R
Kidney Int; 2001 Jun; 59(6):2084-94. PubMed ID: 11380810
[TBL] [Abstract][Full Text] [Related]
37. Role of syndecan-4 in breast cancer pathophysiology.
Onyeisi JOS; Lopes CC; Götte M
Am J Physiol Cell Physiol; 2022 Nov; 323(5):C1345-C1354. PubMed ID: 36094435
[TBL] [Abstract][Full Text] [Related]
38. LHX6 inhibits the proliferation, invasion and migration of breast cancer cells by modulating the PI3K/Akt/mTOR signaling pathway.
Bi QJ; Men XJ; Han R; Li GL
Eur Rev Med Pharmacol Sci; 2018 May; 22(10):3067-3073. PubMed ID: 29863252
[TBL] [Abstract][Full Text] [Related]
39. PLCA8 suppresses breast cancer apoptosis by activating the PI3k/AKT/NF-κB pathway.
Mao M; Chen Y; Jia Y; Yang J; Wei Q; Li Z; Chen L; Chen C; Wang L
J Cell Mol Med; 2019 Oct; 23(10):6930-6941. PubMed ID: 31448883
[TBL] [Abstract][Full Text] [Related]
40. Effects of syndecan-4 gene silencing by micro RNA interference in anoikis resistant endothelial cells: Syndecan-4 silencing and anoikis resistance.
Onyeisi JOS; Pernambuco Filho PCA; Mesquita APS; Azevedo LC; Nader HB; Lopes CC
Int J Biochem Cell Biol; 2020 Nov; 128():105848. PubMed ID: 32927086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
